Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Accelerated Access Proposals Due Out Soon

Executive Summary

UK proposals to promote innovation and speed access to promising new drugs could among other things prompt new payment models. The final report on the government’s Accelerated Access Review should be out by the end of the month.

You may also be interested in...



UK Election Extends Industry Wait For Accelerated Access Review Response

The UK government’s response to the Accelerated Access Review report is on hold until after the snap general election in June.

New Welsh Fund Will Give Quicker Access To New Drugs Than In England Or Scotland

A new fund is expected to help remove uncertainties around the financing of new treatments in the future. It introduces new timelines for health boards to ensure that innovative medicines approved by NICE or the Welsh AWMSG are made available faster to eligible patients on the NHS.

Progress Report On UK's Early Access Scheme: A Limited Success But Could Do Better

The UK's early access to medicines scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed. Sten Stovall talks to those in the industry that have first-hand experience of the process.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel